Delivery Order SPE2DB20D3101-SPE2DB25FRRD8
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $1,954.87. The award was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed-price arrangement with a ceiling value of $22,475.14. This non-set-aside, competitively awarded delivery order is scheduled for completion by July 28, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,466.25 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count). This is a firm fixed-price delivery order with no set-aside designation, executed through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg with a ceiling value of $5,936.37. This competitively awarded, firm fixed-price delivery order was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract represents a pharmaceutical supply fulfillment supporting federal medical procurement needs, with performance occurring at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,526.92 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on July 24, 2025, with a completion date of July 25, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract with a ceiling value of $24,364.10 and an ultimate completion date of July 22, 2025. This is a non-set-aside competitive award, with performance to be executed at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count) with a ceiling value of $1,625.31. This competitively awarded, firm fixed price delivery order is scheduled for completion by July 24, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $25,366.11 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xifaxan is a non-systemic antibiotic used primarily in the treatment of traveler's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $10,087.24 firm fixed-price contract provides the DLA with 4,563,517,205 units of the drug Xifaxan 550 mg tablets. The contract has a completion date of February 2, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a $39,961.11 firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of XIFAXAN 550 MG tablets. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00, to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRD8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $71,126.78. The award was made on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. As a prime vendor for the DLA Medical Supply Chain, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs and federal medical procurement needs. The company's extensive federal contract portfolio demonstrates consistent capability to deliver brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $71.1k | 7/28/25 |